Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
arcticnovartis
Mon, 06/02/2025 – 07:19
Read more about Novartis Pluvicto™ …
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis
Sun, 06/01/2025 – 15:04
Read more about Novartis Kisqali® reduces risk of recurrence in younger patients with ear…
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis
Sun, 06/01/2025 – 15:04
Read more about Novartis Kisqali® reduces risk of recurrence in younger patients with ear…
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
arcticnovartis
Tue, 05/27/2025 – 14:04
Read more about Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2…
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04
Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04
Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04
Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis erzielt im zweiten Quarta…
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis erzielt im zweiten Quarta…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Scembl…
